Caribou Biosciences (CRBU) News Today → Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad) Free CRBU Stock Alerts $1.95 -0.14 (-6.70%) (As of 06/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 5 at 3:56 AM | americanbankingnews.comCaribou Biosciences (NASDAQ:CRBU) Price Target Cut to $9.00 by Analysts at HC WainwrightJune 4, 2024 | marketbeat.comCaribou Biosciences (NASDAQ:CRBU) Price Target Lowered to $9.00 at HC WainwrightHC Wainwright decreased their price objective on Caribou Biosciences from $24.00 to $9.00 and set a "buy" rating on the stock in a report on Tuesday.June 4, 2024 | americanbankingnews.comCaribou Biosciences (NASDAQ:CRBU) Lowered to "Inline" at Evercore ISIJune 3, 2024 | marketbeat.comCaribou Biosciences (NASDAQ:CRBU) Downgraded by Evercore ISI to InlineEvercore ISI lowered Caribou Biosciences from an "outperform" rating to an "inline" rating and lowered their price target for the stock from $13.00 to $3.00 in a research report on Monday.June 2, 2024 | globenewswire.comCaribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMay 30, 2024 | globenewswire.comCaribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor ConferencesMay 23, 2024 | marketbeat.comAssenagon Asset Management S.A. Sells 2,231,947 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU)Assenagon Asset Management S.A. trimmed its stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 98.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,592 shares of the compMay 17, 2024 | marketbeat.comCaribou Biosciences, Inc. (NASDAQ:CRBU) Short Interest UpdateCaribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) saw a significant decline in short interest during the month of April. As of April 30th, there was short interest totalling 10,640,000 shares, a decline of 6.2% from the April 15th total of 11,340,000 shares. Based on an average daily trading volume, of 1,620,000 shares, the short-interest ratio is presently 6.6 days. Currently, 13.4% of the shares of the company are sold short.May 16, 2024 | markets.businessinsider.comExpert Ratings For Caribou BiosciencesMay 13, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Caribou Biosciences (NASDAQ:CRBU)HC Wainwright restated a "buy" rating and set a $24.00 price target on shares of Caribou Biosciences in a report on Monday.May 13, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Caribou Biosciences (CRBU) and Mettler-Toledo (MTD)May 12, 2024 | investorplace.com3 Underappreciated Stocks That Could 10x in 10 YearsMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed: Caribou Biosciences’ Advancing Pipeline and Strong Financials Drive Analyst ConfidenceMay 10, 2024 | marketbeat.comQ2 2024 Earnings Forecast for Caribou Biosciences, Inc. Issued By Brookline Capital Management (NASDAQ:CRBU)Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Equities researchers at Brookline Capital Management reduced their Q2 2024 EPS estimates for shares of Caribou Biosciences in a research note issued on Tuesday, May 7th. Brookline Capital Management analyst L. Cann now forecasts that the comMay 9, 2024 | finance.yahoo.comCaribou Biosciences, Inc. (NASDAQ:CRBU) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMay 7, 2024 | finance.yahoo.comCaribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 7, 2024 | finance.yahoo.comCaribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business UpdateApril 24, 2024 | globenewswire.comCaribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 18, 2024 | seekingalpha.comCaribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring ValueApril 15, 2024 | globenewswire.comCaribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)April 15, 2024 | marketbeat.comVanguard Group Inc. Increases Stock Holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU)Vanguard Group Inc. grew its holdings in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 49.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,822,151 shares of the company's stock after purchasing an addApril 8, 2024 | markets.businessinsider.comBuy Rating Affirmed: Caribou Biosciences’ Promising Trials and Strategic Market PositioningApril 5, 2024 | msn.comKura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market SessionApril 5, 2024 | finanznachrichten.deCaribou Biosciences, Inc.: Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in LupusApril 4, 2024 | globenewswire.comCaribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in LupusApril 2, 2024 | marketbeat.comShort Interest in Caribou Biosciences, Inc. (NASDAQ:CRBU) Increases By 7.2%Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 10,070,000 shares, an increase of 7.2% from the February 29th total of 9,390,000 shares. Based on an average daily volume of 1,650,000 shares, the short-interest ratio is currently 6.1 days. Approximately 12.7% of the company's stock are short sold.April 1, 2024 | finance.yahoo.comWith 65% institutional ownership, Caribou Biosciences, Inc. (NASDAQ:CRBU) is a favorite amongst the big gunsMarch 29, 2024 | marketbeat.comAssenagon Asset Management S.A. Has $12.94 Million Stock Holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU)Assenagon Asset Management S.A. lowered its position in Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 14.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,258,539 shares of the company's stock after sellingMarch 25, 2024 | marketbeat.comCaribou Biosciences (NASDAQ:CRBU) Stock Price Up 6.5%Caribou Biosciences (NASDAQ:CRBU) Shares Up 6.5%March 21, 2024 | marketbeat.comQ1 2024 EPS Estimates for Caribou Biosciences, Inc. (NASDAQ:CRBU) Lifted by HC WainwrightCaribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - HC Wainwright increased their Q1 2024 earnings per share estimates for Caribou Biosciences in a research note issued on Tuesday, March 19th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.39) per shareMarch 19, 2024 | marketbeat.comCaribou Biosciences (NASDAQ:CRBU) Shares Gap Up After Analyst UpgradeCaribou Biosciences (NASDAQ:CRBU) Shares Gap Up on Analyst UpgradeMarch 19, 2024 | marketbeat.comCaribou Biosciences (NASDAQ:CRBU) Price Target Increased to $24.00 by Analysts at HC WainwrightHC Wainwright lifted their price target on shares of Caribou Biosciences from $23.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday.March 18, 2024 | marketbeat.comFY2024 EPS Estimates for Caribou Biosciences, Inc. Decreased by Cantor Fitzgerald (NASDAQ:CRBU)Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Research analysts at Cantor Fitzgerald dropped their FY2024 earnings per share (EPS) estimates for shares of Caribou Biosciences in a research note issued to investors on Wednesday, March 13th. Cantor Fitzgerald analyst R. Bienkowski now expMarch 15, 2024 | marketbeat.comCaribou Biosciences, Inc. to Post Q1 2024 Earnings of ($0.44) Per Share, Leerink Partnrs Forecasts (NASDAQ:CRBU)Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Research analysts at Leerink Partnrs reduced their Q1 2024 earnings per share (EPS) estimates for Caribou Biosciences in a report released on Tuesday, March 12th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn (March 14, 2024 | finance.yahoo.comCRBU Oct 2024 5.000 putMarch 14, 2024 | msn.comCaribou Biosciences (NASDAQ:CRBU): Recent Price Volatility May Offer Investors an Entry PointMarch 14, 2024 | marketbeat.comQ1 2024 Earnings Estimate for Caribou Biosciences, Inc. Issued By Brookline Capital Management (NASDAQ:CRBU)Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Equities researchers at Brookline Capital Management reduced their Q1 2024 earnings estimates for Caribou Biosciences in a research report issued on Monday, March 11th. Brookline Capital Management analyst L. Cann now expects that the companMarch 13, 2024 | markets.businessinsider.comOptimistic Outlook for Caribou Biosciences with a Buy Rating and $20 Price TargetMarch 13, 2024 | marketbeat.comCaribou Biosciences, Inc. (NASDAQ:CRBU) Expected to Earn FY2028 Earnings of ($0.72) Per ShareCaribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Stock analysts at Brookline Capital Management issued their FY2028 earnings per share estimates for shares of Caribou Biosciences in a research note issued to investors on Monday, March 11th. Brookline Capital Management analyst L. Cann foreMarch 12, 2024 | marketwatch.comCaribou Biosciences Shares Fall on Wall Street MissMarch 12, 2024 | fool.comWhy Caribou Biosciences Stock Is Crashing TodayMarch 12, 2024 | marketbeat.comCaribou Biosciences (NASDAQ:CRBU) Stock Price Down 18.4%Caribou Biosciences (NASDAQ:CRBU) Stock Price Down 18.4%March 12, 2024 | finanznachrichten.deCaribou Biosciences, Inc.: Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 11, 2024 | msn.comCaribou Bioscience GAAP EPS of -$0.39 in-line, revenue of $3.56M misses by $1.05MMarch 11, 2024 | markets.businessinsider.comCaribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 11, 2024 | globenewswire.comCaribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 6, 2024 | finance.yahoo.comCaribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual MeetingMarch 5, 2024 | marketbeat.com165,192 Shares in Caribou Biosciences, Inc. (NASDAQ:CRBU) Acquired by Laurion Capital Management LPLaurion Capital Management LP bought a new position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 165,192 shares of the company's stock, valued at approximately $790,000. LaurioMarch 3, 2024 | marketbeat.comAlkeon Capital Management LLC Has $7.86 Million Stock Position in Caribou Biosciences, Inc. (NASDAQ:CRBU)Alkeon Capital Management LLC lifted its position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 21.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,644,863 shares of the companyMarch 2, 2024 | ca.finance.yahoo.comCRBU Oct 2024 2.500 call Get Caribou Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Gift Could Unleash $51 Billion in New Wealth (Ad)In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”. You just have to make this simple move before July 30, 2024. CRBU Media Mentions By Week CRBU Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRBU News Sentiment▼-0.680.75▲Average Medical News Sentiment CRBU News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRBU Articles This Week▼72▲CRBU Articles Average Week Get Caribou Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Monte Rosa Therapeutics News Today Foghorn Therapeutics News Today Cellectis News Today Vaxart News Today Sangamo Therapeutics News Today bluebird bio News Today Precision BioSciences News Today Atara Biotherapeutics News Today Kezar Life Sciences News Today Scholar Rock News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRBU) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored